Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Putting Idiopathic Hypersomnia Treatment Challenges to Rest: The Latest Evidence on the Safety and Efficacy of Emerging Therapies

Premiere Date: Monday, August 30, 2021

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, August 30, 2022
Note: Credit Is No Longer Available

Faculty

Richard K. Bogan, MD, FCCP, FAASM  Associate Clinical Professor University of South Carolina Medical School, Columbia, SC Medical University of South Carolina, Charleston, SC Principal, Bogan Sleep Consultants, LLC Charleston, SC

Nancy R. Foldvary-Schaefer, DO, MS, FAASM, FAAN, FAES, FACNS  Professor of Neurology Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Director, Cleveland Clinic Sleep Disorders Center Cleveland, OH

Statement of Need

Idiopathic hypersomnia (IH) is a chronic, debilitating condition resulting in excessive daytime sleepiness (EDS) and is frequently accompanied by long nocturnal sleep and/or daytime naps, unrefreshing sleep, and difficulty awakening. IH is associated with a high degree of burden that, until recently, was exacerbated by the absence of any approved treatments. Recent clinical evidence has resulted in the first and only FDA-approved treatment for adults with IH.

This CME Outfitters Snack will examine the latest clinical evidence from the Sleep 2021 Annual Meeting on the safety, efficacy, and dosing of novel treatment strategies for IH, with and without long sleep time.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Evaluate novel strategies for the management of idiopathic hypersomnia, with and without long sleep time, for their benefit in improving excessive daytime sleepiness, symptom severity, and global functioning.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, pulmonologists, psychiatrists, neurologists, primary care physicians, PAs, nurse practitioners, and pharmacists

Credit Information

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOCThrough an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Bogan reports that he receives grants from Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals, U.S.A., Inc. He is on the speakers bureau for Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.

Dr. Foldvary-Schaefer reports that she receives research support from Jazz Pharmaceuticals, Inc.; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. She is on the advisory committee for Jazz Pharmaceuticals, Inc. She is a consultant for Jazz Pharmaceuticals, Inc. Publication Committee.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).